Stockscreener 앱 받기
37.89
0.46%
-0.22
시간 외 거래:
37.89
전일 마감가:
$38.11
열려 있는:
$38.11
하루 거래량:
364.25K
Relative Volume:
0.74
시가총액:
$1.65B
수익:
$384.10M
순이익/손실:
$-9.07M
주가수익비율:
-270.64
EPS:
-0.14
순현금흐름:
$11.10M
1주 성능:
-1.44%
1개월 성능:
+4.71%
6개월 성능:
+103.40%
1년 성능:
+48.82%
1일 변동 폭
$37.09
$38.48
1주일 범위
$37.09
$39.43
52주 변동 폭
$17.82
$39.43
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
37.89 | 2.82B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
141.09 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
439.99 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-29 | 개시 | TD Cowen | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Robeco Institutional Asset Management B.V. Buys New Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to "Hold" at Zacks Research - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Stock Position Reduced by Knights of Columbus Asset Advisors LLC - MarketBeat
Wealth Enhancement Advisory Services LLC Has $430,000 Stake in Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Here's What Could Help Kiniksa Pharmaceuticals International, plc (KNSA) Maintain Its Recent Price Strength - Yahoo Finance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to Buy at Wall Street Zen - MarketBeat
Kiniksa Pharmaceuticals Hits New 52-Week High of USD 39.12 - Markets Mojo
AMI Asset Management Corp Sells 34,547 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 42,000 Shares of Stock - MarketBeat
Kiniksa Pharmaceuticals Hits New 52-Week High of $38.97 - Markets Mojo
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Now Covered by TD Cowen - Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week HighWhat's Next? - MarketBeat
KNSA: TD Cowen Initiates Coverage with 'Buy' Rating and $60 PT | - GuruFocus
TD Cowen Initiates Kiniksa Pharmaceuticals International at Buy With $60 Price Target - MarketScreener
Risk vs reward if holding onto Kiniksa Pharmaceuticals Ltd.Quarterly Investment Review & Long-Term Safe Return Strategies - newser.com
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $45.00 Price Target at Wells Fargo & Company - Defense World
Voya Investment Management LLC Buys 10,878 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program - The Globe and Mail
Wells Fargo Raises KNSA Price Target to $45, Maintains Overweigh - GuruFocus
Wells Fargo & Company Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience - sharewise.com
Strs Ohio Acquires Shares of 26,800 Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Goldman Sachs Group Inc. Has $3.47 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Pallas Capital Advisors LLC Buys New Shares in Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
10,700 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Acquired by Toth Financial Advisory Corp - MarketBeat
Strs Ohio Purchases Shares of 26,800 Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Short Interest Update - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $597,944.00 in Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Holdings Raised by Rhumbline Advisers - Defense World
Kiniksa Pharmaceuticals International, plc (KNSA) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives $41.17 Average PT from Analysts - MarketBeat
What high frequency data says about Kiniksa Pharmaceuticals Ltd.Market Weekly Review & Safe Capital Growth Tips - newser.com
Fred Alger Management LLC Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Holdings Raised by AQR Capital Management LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Purchased by Acadian Asset Management LLC - MarketBeat
Using fundamentals and technicals on Kiniksa Pharmaceuticals Ltd.July 2025 Decliners & Long-Term Growth Plans - newser.com
Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN
Backtesting results for Kiniksa Pharmaceuticals Ltd. trading strategiesRisk Management & Free High Accuracy Swing Entry Alerts - newser.com
Exploring High Growth Tech Stocks in the US Market September 2025 - simplywall.st
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month HighStill a Buy? - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells 3,523 Shares of Stock - MarketBeat
Eben Tessari Sells 13,389 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 85,271 Shares of Stock - MarketBeat
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal - The Globe and Mail
American Century Companies Inc. Trims Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kiniksa Pharmaceuticals International Plc 주식 (KNSA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tessari Eben | CHIEF OPERATING OFFICER |
Sep 29 '25 |
Sale |
38.33 |
42,000 |
1,609,860 |
34,552 |
1.54%
1.16%
자본화:
|
볼륨(24시간):